BidaskClub upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a research note released on Friday morning.

Other equities research analysts have also recently issued research reports about the stock. ValuEngine cut shares of Minerva Neurosciences from a strong-buy rating to a buy rating in a report on Tuesday, December 18th. Zacks Investment Research upgraded shares of Minerva Neurosciences from a hold rating to a buy rating and set a $12.00 target price on the stock in a report on Friday, November 9th.

NASDAQ:NERV opened at $7.59 on Friday. Minerva Neurosciences has a 52 week low of $5.00 and a 52 week high of $12.95. The company has a market cap of $295.81 million, a PE ratio of -7.03 and a beta of 1.60.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.07. As a group, sell-side analysts forecast that Minerva Neurosciences will post -1.28 EPS for the current year.

In related news, Director William F. Doyle bought 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 11th. The shares were bought at an average price of $7.97 per share, for a total transaction of $47,820.00. Following the completion of the acquisition, the director now owns 16,611 shares of the company’s stock, valued at approximately $132,389.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Geoff Race sold 5,999 shares of the firm’s stock in a transaction that occurred on Monday, December 17th. The stock was sold at an average price of $7.46, for a total transaction of $44,752.54. Following the completion of the sale, the chief financial officer now owns 204,369 shares in the company, valued at approximately $1,524,592.74. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 10,000 shares of company stock worth $77,220 and sold 16,007 shares worth $120,971. Company insiders own 9.60% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc boosted its stake in shares of Minerva Neurosciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 1,537,590 shares of the biopharmaceutical company’s stock worth $19,297,000 after acquiring an additional 16,956 shares during the last quarter. Marshall Wace North America L.P. boosted its stake in shares of Minerva Neurosciences by 33.2% during the 3rd quarter. Marshall Wace North America L.P. now owns 555,675 shares of the biopharmaceutical company’s stock worth $6,974,000 after acquiring an additional 138,475 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Minerva Neurosciences by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,537,590 shares of the biopharmaceutical company’s stock worth $19,297,000 after acquiring an additional 16,956 shares during the last quarter. TIAA CREF Investment Management LLC boosted its stake in shares of Minerva Neurosciences by 23.4% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 209,195 shares of the biopharmaceutical company’s stock worth $2,625,000 after acquiring an additional 39,721 shares during the last quarter. Finally, MetLife Investment Advisors LLC boosted its stake in shares of Minerva Neurosciences by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 25,297 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 8,993 shares during the last quarter. Institutional investors and hedge funds own 75.09% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Featured Story: How dollar cost averaging works

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.